Allergan Aesthetics, an AbbVie company, announced the Journal of Cosmetic Dermatology published results from a year-long, post-hoc analysis of patient-reported outcomes (PROs) from two Phase 3 clinical studies evaluating the impact of onabotulinumtoxinA (BOTOX Cosmetic) on upper facial lines (UFLs) in adults new to toxin treatment. The peer-reviewed study found that, 30 days after receiving treatment, 90.5% of all study patients reported being either mostly or very satisfied with receiving a natural look, as rated on a five-point scale. This satisfaction was sustained by more than 80% of patients throughout the 12-month study period for the temporary improvement in the appearance of their moderate to severe UFLs. In addition, 30 days after receiving treatment, more than half of treated patients reported an improvement in self-perceived appearance and psychological well-being, defined as those who achieved a meaningful improvement in five areas (how much their facial lines made them feel older, feel unhappy, look angry, look tired, or feel that they negatively affected self-esteem).

UFLs, which include forehead, glabellar, and crow's feet lines, fall within the main areas of concern for individuals considering aesthetic treatments. The study, titled Self-Perception of Natural Outcome, Appearance and Emotional Well-Being After OnabotulinumtoxinA Treatment for Upper Facial Lines: Post-Hoc Analysis Across Age and Gender, analyzed patient-reported outcomes (PROs) from more than 450 neurotoxin-naïve adults treated who saw a reduction in UFL severity with onabotulinumtoxinA (BOTOX Cosmetic). The study used the Facial Line Satisfaction Questionnaire, a validated proprietary questionnaire developed according to FDA guidelines for PRO measures, which assesses treatment satisfaction, appearance, and emotional impact as perceived by patients.

Read more at AbbVie >>